BlackRock has joined the University of Dundee spinout’s series C round, following a $60m first close in May last year.

Exscientia, a UK-based drug discovery technology spinout of University of Dundee, increased its series C round to $100m yesterday following a $40m extension supplied by funds managed by BlackRock.
Pharmaceutical firm Novo led a $60m initial tranche in May 2020, which also featured its peer Bristol Myers Squibb as well as drug discovery and development company Evotec and private equity firm GT Healthcare Capital, through unnamed limited partners.
Exscientia exploits artificial intelligence technology to precisely engineer drug…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in